[Acute management of cerebral infarction].
Araúz
Antonio
A
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, México, D.F.
Barinagarrementeria
Fernando
F
Navarrete
Hugo
H
Ascanio
Gabriel
G
Osorno
Miguel
M
Miranda
Luis
L
Alegría
Marco Antonio
MA
Escamilla
Juan Manuel
JM
Cantú
Carlos
C
D000208:Acute Disease; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D019090:Case Management; D002544:Cerebral Infarction / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D005060:Europe; D019317:Evidence-Based Medicine; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D015337:Multicenter Studies as Topic; D009316:National Institutes of Health (U.S.); D018696:Neuroprotective Agents / Q000627:therapeutic use; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014481:United States
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D018696:Neuroprotective Agents; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator